

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	X

## Mulpleta (lustrombopag)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Mulpleta (lustrombopag)	May be subject to quantity limit

### APPROVAL CRITERIA

Requests for Mupleta (lusutrombopag) may be approved if the following criteria are met:

- I. Individual is 18 years of age or older; **AND**
- II. Individual is diagnosed with thrombocytopenia; **AND**
- III. Individual has a platelet count of less than  $50 \times 10^9/L$ ; **AND**
- IV. Individual has chronic liver disease; **AND**
- V. Individual is using prior to a planned procedure.

Mulpleta (lustrombopag) may not be approved for the following:

- I. Used to normalize platelet counts in those with chronic liver disease.

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

### Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2018. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Updated periodically.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.  
CRX-ALL-0412-19

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
<b>Applicable</b>	X	X	X	X	X	X	X

4. Hicks LK, Bering H, Carson KR, et al. Five hematologic tests and treatments to question. *Blood*. 2014; 124(24):3524-3528. Available from: <http://www.bloodjournal.org/content/bloodjournal/124/24/3524.full.pdf?sso-checked=true>. Accessed on: March 12, 2019.
5. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2018; Updated periodically.
6. Mupleta [Package insert]. Florham Park, NJ. Shionogi Inc; 2018. Available at [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2018/210923s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210923s000lbl.pdf) Accessed on: March 12, 2019.
7. Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. *Blood*. 2011; 117(16):4190-4207. Available from: <http://www.hematology.org/Clinicians/Guidelines-Quality/Guidelines.aspx>. Accessed on: March 14, 2019.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.  
CRX-ALL-0412-19